Clinical trial
Adjuvant Therapy for High-Risk Breast Cancer With Wkly Adriamycin & Oral Cytoxan…
NCT00194753 · University of Washington, Other · Completed
Key facts
| NCT number | NCT00194753 |
|---|---|
| Title | Adjuvant Therapy for High-Risk Breast Cancer With Wkly Adriamycin & Oral Cytoxan With G-CSF for 12 Wks; Wkly Taxol x 12 |
| Official title | Adjuvant Therapy for High-Risk Localized Breast Cancer With Weekly Adriamycin +/- Oral Cytoxan With Continuous G-CSF Support for 12 Weeks Followed by Weekly Taxol for 12 Weeks, Phase II |
| Lead sponsor | University of Washington, Other |
| Collaborators | Amgen Industry Bristol-Myers Squibb |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Breast Neoplasm |
| Intervention type | Drug |
| Interventions | Paclitaxel, Doxorubicin, Cyclophosphamide, G-CSF |
| Enrollment | 80 |
| Start date | Dec 1, 2001 |
| Primary completion | Mar 1, 2011 |
| Completion | Mar 1, 2011 |
| First posted | Sep 19, 2005 |
| Last update posted | Sep 13, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: